Athos Capital Ltd Buys Shares of 100,000 Avanos Medical, Inc. $AVNS

Athos Capital Ltd purchased a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 100,000 shares of the company's stock, valued at approximately $2,488,000. Avanos Medical accounts for about 0.9% of Athos Capital Ltd's portfolio, making the stock its 21st largest position. Athos Capital Ltd owned about 0.21% of Avanos Medical at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC increased its position in shares of Avanos Medical by 132.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company's stock valued at $28,000 after buying an additional 1,423 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company's stock valued at $31,000 after acquiring an additional 2,307 shares during the last quarter. Wexford Capital LP purchased a new position in Avanos Medical during the 3rd quarter valued at about $70,000. Longfellow Investment Management Co. LLC purchased a new position in Avanos Medical during the 2nd quarter valued at about $75,000. Finally, Tower Research Capital LLC TRC raised its position in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company's stock worth $77,000 after acquiring an additional 5,083 shares during the last quarter. Institutional investors and hedge funds own 95.17% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AVNS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Avanos Medical in a report on Monday, July 20th. Zacks Research upgraded Avanos Medical from a "strong sell" rating to a "hold" rating in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce".

Avanos Medical Stock Performance

Avanos Medical stock opened at $24.99 on Monday. The firm has a market capitalization of $1.17 billion, a P/E ratio of -15.52 and a beta of 1.57. The stock has a fifty day moving average price of $24.96 and a 200 day moving average price of $21.06. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $25.49. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical, Inc. (NYSE:AVNS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source